[0009] In one aspect, the present disclosure refers to an saRNA, wherein the saRNA comprises GACCAGUGACAAUGACCGCUU as an antisense sequence and GCGGUCAUUGUCACUGGUCUU as a sense sequence. In another aspect the present disclosure refers to an saRNA wherein the saRNA consists of (invabasic)gcGgUCAUUgUCAcUGGUCuu as a sense sequence and GACCAGUGACAAUGACCGCuu as an antisense sequence, wherein lower case letters indicate 2'O-Me modification and "invabasic" refers to an inverted abasic modification at the 5' end. In another aspect, the present disclosure refers to a pharmaceutical composition comprising the saRNA as disclosed herein and at least one pharmaceutically acceptable carrier. One example discloses a pharmaceutical composition comprising a saRNA that targets a C/EBPα transcript and at least one pharmaceutically acceptable carrier.

[0010] Another example discloses a method of modulating the metabolic pathway of a subject comprising administering a saRNA that targets a C/EBPα transcript to said subject.

[0011] Another example discloses a method of inhibiting the proliferation of hyperproliferative cells comprising contacting the cells with a saRNA that targets a C/EBPα transcript.

[0012] Another example discloses a method of treating or preventing hyperproliferative disorders comprising administering a saRNA that targets a C/EBPα transcript to a subject with said hyperproliferative disorder.

[0013] Another example discloses a method of regulating epithelial-mesenchymal transition of a cell comprising contact the cell with a saRNA that targets a C/EBPα transcript.

[0014] Yet another example discloses a method of regulating stem cell differentiation and pluripotency comprising contact said stem cell with a saRNA that targets a C/EBPα transcript.

Claims

1. An saRNA, wherein the saRNA comprises GACCAGUGACAAUGACCGCUU as an antisense sequence and GCGGUCAUUGUCACUGGUCUU as a sense sequence.

2. A pharmaceutical composition comprising the saRNA of claim 1 and at least one pharmaceutically acceptable carrier.

3. The saRNA or composition of claim 1 or 2, wherein the saRNA comprises one or more modifications to a sugar, a nucleobase, and/or an internucleoside linkage, or wherein the saRNA does not comprise one or more modifications to a sugar, a nucleobase, and/or an internucleoside linkage.

4. The saRNA or composition of any one of claims 1-3, wherein the sense sequence does not comprise one or more modifications to a sugar, a nucleobase, and/or an internucleoside linkage.

5. The saRNA or composition of claim 4, wherein the sense and antisense sequences do not comprise one or more modifications to a sugar, a nucleobase, and/or an internucleoside linkage.

6. The saRNA or composition of any one of claims 1-3, wherein the antisense sequence consists of GACCAGUGACAAUGACCGCuu, wherein lower case letters indicate 2'O-Me modification.

7. An saRNA, wherein the saRNA consists of (invabasic)gcGgUCAUUgUCAcUGGUCuu as a sense sequence and GACCAGUGACAAUGACCGCuu as an antisense sequence, wherein lower case letters indicate 2'O-Me modification and “invabasic” refers to an inverted abasic modification at the 5’ end.

8. A pharmaceutical composition comprising the saRNA of claim 7 and at least one pharmaceutically acceptable carrier.